You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company attributed the increase predominantly to a continued adoption of its infectious disease menu by US microbiology laboratories.
The company's quarterly revenue of $13.2 million and net loss of $.21 per share beat analysts' estimates.
The company said revenues from its ConfirmMDx prostate cancer test rose 62 percent in 2015, and that testing volume exceeded 15,000 patients.
On an adjusted basis and at constant exchange rates, Q4 revenues increased about 3 percent year over year, but fell short of previously stated guidance of 5 percent growth.
The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.
Danaher's full-year revenues rose nearly 8 percent with its life sciences and diagnostics business its best-earning segment for both Q4 and FY2015.
The company projects revenues will rise 39 percent year over year in Q4, and 53 percent year over year for 2015.
The firm also reaffirmed is guidance for EPS for the fourth quarter of 2015 in advance of an investor meeting in New York.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
For the quarter ended Sept. 30, Cepheid reported preliminary revenue of approximately $126.5 million, shy of the Wall Street estimate of $127.8 million.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.